The pharmaceutical boom in weight-loss drugs has put companies like Novo Nordisk and Eli Lilly in ever-fiercer competition. Now more heavyweights, like Pfizer and Astrazeneca, are entering the ring. Who will come out on top? Global pharmaceutical companies are racing to own the market for GLP-1 weight loss drugs, which have the potential to treat millions of patients. Novo Nordisk, the original pioneer, has ceded market share to fast-moving competitor Eli Lilly, and now other giants like Pfizer

Tag-uri: Pfizer